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BACKGROUND: Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid
(ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease
outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the
primary tumour between treatment groups.
METHODS: In total, 205 patients received neoadjuvant CT±ZOL (CTþZOL, n¼102; CT, n¼103). The primary end point was
pathologically assessed residual invasive tumour size (RITS) at surgery. Secondary end points were pathological complete response
(pCR) rate and axillary nodal involvement. Following review of surgical pathology reports (n¼195), outcome differences between
groups were assessed adjusting for potential response modifiers.
RESULTS: Baseline characteristics and CT treatments were similar. In multivariate analysis, allowing for biological and clinical factors
known to influence tumour response, the adjusted mean RITS in CT and CTþZOL groups were 27.4 and 15.5mm, respectively,
giving a difference in means of 12mm (95% confidence interval: 3.5–20.4mm; P¼0.006). The pCR rate was 6.9% in the CT group
and 11.7% in the CTþZOL group (P¼0.146). There was no difference in axillary nodal involvement (P¼0.6315).
CONCLUSION: These data suggest a possible direct anti-tumour effect of ZOL in combination with CT, warranting formal evaluation in
prospective studies.
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BACKGROUND
Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate
(N-BP), is firmly established in the management of metastatic bone
disease. It inhibits farnesyl diphosphate synthase within the
mevalonate pathway and, through this mechanism, is a potent
inhibitor of osteoclast-mediated bone resorption. In addition,
there are pre-clinical data indicating that farnesyl diphosphate
synthase inhibition by ZOL has both direct and indirect anti-
tumour effects in breast cancer (Winter et al, 2008). Furthermore,
synergistic anti-tumour effects with chemotherapy (CT) drugs
commonly used in the treatment of breast cancer have been
demonstrated. Recently, it has been reported that sequential
treatment with doxorubicin followed by ZOL at clinically relevant
doses elicited substantial anti-tumour effects in in vivo mouse
models of subcutaneous breast tumours (Ottewell et al, 2008). The
clinical evidence of an anti-tumour effect of ZOL, however, is
uncertain, although recent data suggest that the addition of ZOL to
endocrine treatments improves disease outcomes in pre-meno-
pausal women with early breast cancer (Gnant et al, 2009).
Inconclusive results from adjuvant trials of the oral bisphos-
phonate, clodronate, in the 1990s formed the rationale for adjuvant
trials of the more potent ZOL. It was anticipated that ZOL might
have more definite beneficial anti-tumour effects. This could occur
‘indirectly’ through the inhibition of bone resorption and
consequent reduction in bone-derived factors that disrupt the
inter-relationships between cancer, bone and haematopoetic stem
cell populations, thereby creating a less favourable microenviron-
ment for the survival of metastatic tumour cells. Alternatively, or
perhaps in addition, ‘direct’ effects such as induction of tumour
cell apoptosis, reduction in proliferation rates and tumour
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sangiogenesis, as well as potential synergistic effects with anti-
cancer therapies, might be clinically important (Coleman, 2007).
The AZURE trial (ISRCTN 79831382; BIG 01/04) is an academic
study run by the National Institute for Health Research National
Cancer Research Network (NIHR NCRN) in the United Kingdom
with input from international collaborative groups. The study
randomised 3360 women with axillary node-positive stage II/III
breast cancers to determine whether the addition of ZOL to
systemic therapy improves disease-related outcomes (Figure 1).
Analysis and reporting of the AZURE trial awaits the occurrence of
a pre-specified number of disease-free survival events. However,
within this large study, B6% of patients received neoadjuvant CT
(Figure 1). In light of the pre-clinical data and emerging clinical
evidence of a potential anti-tumour effect of ZOL, we have
conducted an exploratory retrospective evaluation of this sub-
group. The objective was to determine whether the addition of ZOL
to primary systemic neoadjuvant CT had any demonstrable
influence on pathological response in the surgical resection
specimen compared with the effects of neoadjuvant CT alone.
PATIENTS AND METHODS
Patient population
Of the 3360 patients recruited, the treating physicians elected to
treat 205 patients with neoadjuvant CT. Patients receiving
neoadjuvant CT on the AZURE trial were required to have either
stage T3 or T4 disease, or biopsy-proven lymph node involvement
(N1), and be scheduled to proceed to definitive surgery and/or
radical radiotherapy with curative intent within 6 months of
starting therapy.
Using a minimisation technique to randomise patients, the two
groups were well balanced for T-stage, lymph node involvement,
oestrogen receptor (ER) status, neoadjuvant systemic treatment
plan and CT type (anthracycline/taxane), menopausal status, the
use of statins (which also act on the mevalonate pathway) and
treatment centre.
Baseline tumour size per se was not prospectively collected in
AZURE. Furthermore, inherent problems exist related to inter-observer
variability in the clinical assessment of breast tumour size and
discrepancies between physical examination, mammographic and
ultrasound estimates of size. We therefore instead incorporated
tumour (T) stage, determined by clinical examination, into the
statistical analysis, as this was a prospectively collected tumour
characteristic. However, we also sought information from centres
on baseline tumour measurements by clinical, ultrasound and/or
mammographic assessment to enable sensitivity analyses.
Details of surgery and pathological response
Histopathologically assessed residual invasive tumour size (RITS)
is reported on breast cancer pathology reports as part of the
minimum data set, and the largest dimension of dominant invasive
tumour focus is routinely recorded (NHS Breast Cancer Screening
Programme (NHSBSP) and The Royal College of Pathologists,
2005). These data and the number of positive axillary lymph nodes
at the time of definitive surgery were prospectively specified to be
collected in AZURE, enabling the primary and secondary end
points of this analysis to be determined.
The conventional end point of neoadjuvant CT studies in breast
cancer is pathological complete response (pCR), representing the
most robust surrogate marker of longer-term outcome (Fisher
et al, 1997, 1998; van der Hage et al, 2001; Heys et al, 2002; Bear
et al, 2006; Mieog et al, 2007). However, the definition of this has
not been applied in a consistent and standardised manner
throughout clinical trials (Kuroi et al, 2005). As AZURE was not
primarily a neoadjuvant study, data regarding attainment of pCR
were not prospectively collected. However, following a blinded
central review of pathology reports, pCR was considered to have
been achieved if the pathology report specifically indicated an
absence of any residual invasive tumour within the breast and
axilla, as per the recommended optimum definition (Gralow et al,
2008).
Determining RITS and nodal status
In cases in which there was no residual invasive tumour, ‘0mm’
was recorded. In cases in which multifocal pathology was present
(n¼25), the largest dimension of residual invasive tumour focus
Subset of 3360 patients randomised to AZURE who
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Figure 1 AZURE trial schema. (Does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?)
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swas recorded. Occasionally, if a measurement of the largest focus
was not given, but the overall size including invasive tumour
islands was reported, this was recorded.
For the assessment of axillary nodal disease after CT, the
number of positive axillary nodes (and total number of nodes
resected) was recorded. No distinction between axillary nodal
micrometastases (40.2–o2mm) and overt metastases (X2mm)
was made, with both considered as evidence of nodal metastasis.
Treatment
Case report forms were also evaluated to review details of
neoadjuvant systemic treatments received. Duration of treatment
was defined as the time from the first CT to surgery in days.
Patients received neoadjuvant CT as per local guidelines. In light of
the pre-clinical data, it was mandated that ZOL should be given
after CT. Patients received ZOL as a 4mg intravenous dose, given
in 100ml 0.9% normal saline over 15min.
Statistical methodology
The primary end point for this study was RITS (mm) in the
surgical resection specimen. Secondary end points included the
number of positive axillary nodes (categorised as 0, 1–3, 4þ
positive nodes) and pCR (%), as previously defined. Only pre-
defined end points were subjected to statistical testing using a 5%
(two-sided) significance level. All other data were summarised
descriptively. As this was an exploratory evaluation, patients were
analysed on a per protocol basis, with one patient randomised to
CTþZOL but who never started study treatment included in the
CT control arm.
For the primary end point, the outcome difference between the
two groups was compared using linear regression, adjusting for the
following potential prognostic factors: tumour stage (T2, T3 or T4,
at the time of randomisation), ER status, PgR status, menopausal
status, CT type (anthracycline, taxane) and treatment duration.
Patients with missing data for PgR status and treatment duration
(n¼8) were included as ‘unknown’ PgR status and ‘6 months’,
respectively, representing the maximum time between the
commencement of neoadjuvant therapy and definitive surgery
allowed by the study protocol. A sensitivity analysis was also
performed that adjusted for clinical baseline tumour size, instead
of tumour stage, and the other factors as above.
Axillary nodal status was compared between the two treatment
groups using ordered logistic regression to adjust for the factors as
described above. The difference between treatment groups in the
proportion of patients with pCR was compared using logistic
regression, adjusting for the previously described factors. Missing
data for PgR status and treatment duration (n¼8) were
substituted as above.
HER2/neu status was not routinely assessed at the time of trial
recruitment. Furthermore, very few patients received trastuzumab
in the neoadjuvant treatment period (n¼6). Tumour grade was
not included in multivariate analysis, as grade, in most UK centres,
is not routinely assessed on diagnostic core specimens because of
concerns regarding possible tumour heterogeneity and sampling
error. It is also difficult to evaluate post-treatment grade reliably
because of CT-induced cytological and histological changes
(Kurosumi, 2006).
Role of the funding source
The trial design was reviewed and approved by Cancer Research
UK’s Clinical Trials Awards and Advisory Committee for access to
NIHR NCRN resources. The research costs were supported by a
grant from Novartis to the University of Sheffield, the sponsor of
the study. The funders had no part in data collection and analysis,
interpretation of data or writing the paper. The corresponding
author had full access to the data and final responsibility for the
decision to submit for publication.
RESULTS
Of the 205 patients who received neoadjuvant CT, 103 patients
were randomised to CT alone and 102 to CTþZOL. Of these, 195
(95.1%) surgical histopathology forms were available for central
review, blinded to treatment allocation, and were included in these
exploratory analyses; 94 received CTþZOL and 101 received CT
alone. Ten patients were excluded because of missing pathology
reports (n¼8), no surgery (n¼1) or patient death before surgery
(n¼1).
Clinicopathological baseline characteristics are shown in Table 1.
Age and menopausal status of patients in both groups were similar,
although there were 10 more pre-menopausal patients in the
CT-alone group. The majority of patients presented with T3 or T4
tumours and most had unknown lymph node involvement before
Table 1 Patient characteristics
Chemotherapy
alone n¼101 (%)
Chemotherapy+
zoledronic acid
n¼94 (%)
Median age in years (IQR) 48 (41–54) 47 (42–57)
T-stage (at time of randomisation)
T2 1 (1) 3 (3.2)
T3 55 (54.5) 54 (57.4)
T4 45 (44.6) 37 (39.4)
Axillary lymph involvement (at time of randomisation)
1–3 6 (5.9) 6 (6.4)
Unknown 95 (94.1) 88 (93.6)
Menopausal status
Pre 65 (64.4) 55 (58.5)
Post 28 (27.7) 31 (33)
Unknown 8 (7.9) 8 (8.5)
ER status
+ve 65 (64.4) 64 (68.1)
 ve 36 (35.6) 30 (31.9)
PgR status
+ve 25 (24.8) 32 (34)
 ve 46 (45.5) 33 (35.1)
Unknown 30 (29.7) 29 (30.9)
HER2 status
+ve 22 (21.8) 14 (14.9)
 ve 47 (46.5) 49 (52.1)
Not measured 26 (25.7) 24 (25.5)
Unknown 6 (5.9) 7 (7.4)
Histology
Ductal 78 (77.2) 75 (79.8)
Lobular 12 (11.9) 7 (7.4)
Other 7 (6.9) 10 (10.6)
Unknown 4 (4) 2 (2.1)
Median number of lymph
nodes examined (IQR)
15 (11–19) 14 (11–19)
Median tumour size in mm (IQR)
Clinical (n¼144–74%) 70 (60–100) 60 (40–70)
Ultrasound (n¼91–47%) 32 (25–46) 31 (26–40)
Mammogram (n¼67–34%) 40 (30–60) 35 (27–41)
Abbreviations: ER¼oestrogen receptor; IQR¼interquartile range; PgR¼
progesterone receptor.
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sthe commencement of CT. Table 1 also shows median and
interquartile range (IQR) for baseline tumour size by clinical,
ultrasound and/or mammographic assessment where available.
The frequency of ER-negative tumours, an important predictor of
CT response (MacGrogan et al, 1996; Kaufmann et al, 2007), was
similar in the groups. In approximately one-third of patients, PgR
status was unknown (either missing or not performed in some
recruiting centres). This trial began before the routine use of
trastuzumab in adjuvant therapy and HER2 status was unknown in
32.3% of patients.
Details of systemic treatment received are shown in Table 2.
Treatment duration and the number of CT cycles were comparable
in both groups. Dose intensities were similar between the two
treatment groups (data not shown).
Residual invasive tumour size
Residual invasive tumour size could be determined in 182 patients
(93 CT alone and 89 CTþZOL). In the remaining 13 patients, 1
patient developed progressive disease during neoadjuvant CT and
had palliative surgery almost 1 year later. For the remaining 12
patients (n¼8 CT, n¼4C T þZ), the pathology reports gave no
specific measurement of residual microscopic invasive tumour size
describing ‘widespread tumour emboli’ or ‘occasional residual
focus of infiltrating carcinoma’. Putting a measurement on these
cases was not considered valid.
Median RITS was 30mm (IQR 7–60mm) in the CT-alone group
and 21mm (7–38mm) in the CTþZOL treatment group. In
multivariate analysis (Table 3), the adjusted mean RITS in the
CT-alone group was 27.4 and 15.5mm in the CTþZOL group,
giving a statistically significant difference in means of 12mm (95%
CI 3.5–20.4mm, P¼0.0059). In a sensitivity analysis replacing
T-stage with clinical tumour size at baseline, RITS remained
smaller in the CTþZOL group by 9.9mm (95% confidence
interval (CI) 0.2–19.7mm; P¼0.0465, n¼137).
Multivariate analysis (Table 3) also revealed that treatment
duration (P¼0.0011) and taxane-based CT (P¼0.0204) were
significantly associated with RITS, indicating a smaller residual
tumour size with increasing treatment duration and an increased
residual tumour size with the use of taxane CT. This may, however,
simply reflect an increased use of taxanes in patients responding
poorly to the early cycles of anthracycline CT, as 31 patients
planned at the time of randomisation to receive anthracyclines
alone were subsequently switched to a taxane.
Secondary end points
Axillary nodal status Information on the pathological status of
axillary lymph nodes was available from 194 (99.5%) pathology
reports. The median number of positive axillary lymph nodes was
3 (IQR 0–6) in the CT group and 2 (IQR 0–6) in the CTþZOL
group. There was no significant difference in axillary nodal
involvement, categorised by 0 (30.7% CT alone vs 28.7%
CTþZOL), 1–3 (23.8 vs 29.8%) or X4 (45.5 vs 40.4%) positive
nodes, between the treatment groups in multivariate analysis
(P¼0.6315). The only factors that were significantly associated
with a lower number of involved nodes were increasing treatment
duration (P¼0.0102) and ER-negative status (P¼0.0129).
pCR In total, 24 (12.3%) patients had no residual invasive disease
in the breast, 10 (9.9%) patients in the CT-alone group and 14
(14.9%) patients in the CTþZOL group. In all, 18 (9.2%) patients
achieved pCR, defined as ‘the absence of residual invasive tumour
within both breast and axilla’, 7 (6.9%) patients in the CT-alone
group and 11 (11.7%) in the CTþZOL group. Of the patients
achieving pCR, two in the CTþZOL and none in the CT groups
had DCIS present in the absence of any remaining invasive disease.
In multivariate analysis (n¼195) adjusting for potential prog-
nostic factors in addition to neoadjuvant treatment group, a trend
for patients receiving CTþZOL to have increased odds of
achieving pCR (odds ratio¼2.2, 95% CI 0.8–6.3, P¼0.1457) was
seen. Not surprisingly, given the low number achieving pCR, no
statistically significant predictive factors for pCR were identified.
Mastectomy rate Breast conservation surgery is often the
primary aim in patients being treated with neoadjuvant CT, and
therefore mastectomy rate is an important outcome parameter.
Table 2 Neoadjuvant chemotherapy treatments
Chemotherapy
alone
n¼101 (%)
Chemotherapy
+zoledronic
acid
n¼94 (%)
Median duration of treatment
days, (IQR)
145.5 (127.5–184) 148 (130–188)
Median number of chemotherapy
cycles (IQR)
6( 6 – 7 ) 6( 6 – 8 )
Chemotherapy received
Anthracycline based only 46 (45.5) 49 (52.1)
Sequential anthracycline+taxane 50 (49.5) 41 (43.6)
Combination anthracycline+taxane 5 (5) 4 (4.3)
Trastuzumab 4 (4) 2 (2.1)
G-CSF use 18 (17.8) 22 (23.4)
Median number of zoledronic acid
infusions (IQR)
N/A 6 (5–6)
Median number of zoledronic acid
infusions given with chemotherapy (IQR)
N/A 5 (4–6)
Abbreviations: G-CSF¼granulocyte colony-stimulating factor; IQR¼interquartile
range; N/A¼not applicable.
Table 3 Multivariate analysis investigating residual invasive tumour size
by neoadjuvant treatment (adjusting for prognostic factors)
Factor Estimate s.e. 95% CI P-value
Treatment
CT alone vs CT+zoledronic acid 12 4.3 3.5, 20.4 0.0059
T-stage
T2 vs T4  20.7 14.7  49.6, 8.3 0.2870
T3 vs T4 2 4.5  6.8, 10.8
Taxane regimen
Yes vs no 11.9 5.1 1.9, 21.9 0.0204
Treatment duration
a  0.2 0.1  0.3,  0.1 0.0011
ER status
Positive vs negative 10.2 5.4  0.5, 21 0.0609
PgR status
Positive vs negative 0.4 6.2  11.9, 12.7 0.1466
Unknown vs negative  9.2 5.7  20.5, 2.1
Menopausal status
Pre vs post  9.8 4.8  19.3,  0.2 0.0567
Unknown vs post  16.5 8.3  32.9,  0.1
Abbreviations: CI¼confidence interval; CT¼chemotherapy; ER¼oestrogen recep-
tor.
aDefined as time from the first chemotherapy to surgery (days); a negative
estimate indicates tumour size decreasing with increasing treatment duration.
Reference categories are shown in bold. A positive estimate indicates that the
residual invasive tumour size is decreased in the reference category.
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sInitial (as a representation of intent of surgery) type of surgery was
recorded in all patients. Altogether, 80 (79.2%) patients in the
CT-alone group had a mastectomy compared with 66 (70.2%) in
the CTþZOL treatment group.
Safety
The combination of CTþZOL in the neoadjuvant treatment
setting was well tolerated, with no increase in serious adverse event
(SAE) reporting. There were 63 SAEs reported within the median
neoadjuvant treatment period (147 days (IQR 129–184)): 36 events
in the CT-alone group – 16 (44.4%) neutropenic sepsis, 7 (19.4%)
neutropenia, 5 gastrointestinal, 3 pyrexia, 1 ‘other’ infection, 1
rash, 1 pleural effusion, 1 flu-like symptoms and 1 other symptom
– and 27 in the CTþZOL group – 14 (51.9%) neutropenic sepsis, 3
(11.1%) neutropenia, 3 (11.1%) ‘other’ infection, 5 gastrointestinal, 1
anaphylactic reaction and 1 cardiovascular or loss of consciousness.
DISCUSSION
These retrospective exploratory data intriguingly suggest that a
bisphosphonate may have effects on tumours outside bone. An
improved pathological response in patients treated with CTþZOL
compared with CT alone was observed and suggests a possible direct
anti-tumour effect of ZOL in combination with neoadjuvant CT.
There are some limitations to the interpretation of these data.
Firstly, there was no central pathological review of the operative
specimens and therefore probable inter-pathologist variation
existed with respect to specimen processing and pathological
evaluation. Secondly, assessment of RITS is somewhat imprecise,
as asymmetry of residual disease and hypocellularity are not
usually quantified during pathology reporting (Symmans et al,
2007). In addition, missing data may negatively affect the quality of
a retrospective study and, as exploratory end points, these analyses
are likely to be underpowered.
In this study, we have included T-stage to reflect the baseline
extent of primary breast cancer in the main analysis. Baseline
clinical measurements of tumour size were missing in 26% of
patients. In a sensitivity analysis, the replacement of T-stage with
clinical estimates of initial tumour size into the multivariate
analysis did not materially affect the differences in RITS seen
between treatments, with the beneficial effect of ZOL persisting.
The extent of residual tumour following CT has been well
established as an intermediate surrogate end point for longer-term
outcome such as relapse and survival (Carey et al, 2005). However,
no standard validated internationally accepted classification exists
for the reporting of pathological response to neoadjuvant CT.
To date, neoadjuvant studies have used pCR as a validated
intermediate surrogate marker of survival, despite it being a less
common phenomenon. Therefore, for the majority of patients,
‘residual disease’ represents a spectrum ranging from those
patients achieving ‘near’ pCR to those with resistant disease,
potentially associated with widely differing prognoses.
Analysis of RITS potentially allows an exploratory evaluation of
therapeutic effect in those patients achieving less than pCR.
Furthermore, RITS after CT is of potential clinical relevance. In the
largest published single-institution cohort from the MD Anderson
Cancer Center (n¼338), Chen et al (2004) published data on
5-year locoregional recurrence (LRR) rates following neoadjuvant
CT and breast-conserving surgery. Pathologically assessed residual
primary tumour 42cm after neoadjuvant CT and breast-conser-
ving surgery significantly predicted for LRR in multivariate
analysis (hazard ratio 3.2; P¼0.006, along with initial N2/N3
disease, residual multifocal pattern of disease and lymphovascular
space invasion).
Although not widely validated, published studies have shown
that pathological staging, including an evaluation of residual
tumour size after neoadjuvant CT, may be useful in predicting
longer-term outcome. In 2003, a revised AJCC TNM breast cancer
classification was implemented (Greene et al, 2002), designating
the letter ‘y’ to represent pathological stage of residual tumour
after neoadjuvant therapy. Carey et al (2005) reported that higher
pathological stage in the surgical resection specimen using this
revised classification system was significantly associated with
lower rates of distant disease-free survival and overall survival in
stage II/III breast cancer patients treated with neoadjuvant CT
(n¼132, median follow-up 5 years). In addition, the Clinical-
Pathologic Scoring (CPS) system has very recently been described
to predict 5-year outcomes of breast cancer patients treated with
neoadjuvant CT (Jeruss et al, 2008). This model incorporates
clinical TNM stage at presentation and post-neoadjuvant CT
pathological TNM stage, assigning points to each presenting
clinical substage and post-treatment pathological substage, with a
5-year distant metastasis-free survival of 97% for a CPS score of 0
and 46% for a CPS score of 4.
In this analysis, we have reported a trend for a higher
proportion of patients treated with CTþZOL (11.7%) achieving
pCR compared with CT alone (6.9%). It is not surprising that this
is not statistically significant because of the small numbers of
patients involved. Secondly, these figures require a degree of
cautious interpretation, as they represent overall low rates of pCR,
given that pCR rates of up to 30% have been reported in
randomised studies of neoadjuvant CT regimens (Buzdar, 2007).
However, it must be noted that many of the previously published
studies included patients with T1–T2 stage disease, whereas in this
cohort 98% of patients presented with T3–T4 disease.
The presence of nodal disease after neoadjuvant CT is associated
with a poorer prognosis (Kuerer et al, 1999; Rouzier et al, 2002).
We did not show any significant difference in post-treatment nodal
status between the two treatment groups. This may not be
surprising given that axillary lymph node metastases, considered
as disseminated tumour cells, are selectively more resistant than
primary tumour cells (von Minckwitz et al, 2008). However, of
interest, the proportion of patients in the CTþZOL group
achieving pCR (including negative nodal status) was higher than
in the CT-alone group, potentially reflecting increased chemo-
sensitivity of nodal disease with complete pathological response in
the breast, as has been previously described (Kuerer et al, 1999).
These data reported here follow shortly after the most promising
clinical data to date regarding a potential anti-tumour effect of
ZOL in early breast cancer from the ABCSG-12 study report (Gnant
et al, 2009). In this trial, 1803 pre-menopausal women with
endocrine-sensitive breast cancer were randomised to receive
endocrine treatment (gonadotrophin-releasing hormone analogue
and tamoxifen or anastrozole) with or without ZOL (4mg
intravenous infusion) 6 monthly for 3 years. With a median
follow-up of 48 months, the addition of ZOL to endocrine therapy
was associated with a 36% improvement in disease-free survival
compared with endocrine treatment alone (hazard ratio¼0.64
95% CI 0.46, 0.91, P¼0.01). Furthermore, the benefits of ZOL were
not confined to the bone, with a striking reduction in locoregional
and distant extraosseus recurrence events as well. Despite a
relatively low number of events, this is further evidence that ZOL
may exhibit anti-tumour activity in patients with early breast
cancer.
In the clinical setting, there are no fully published data regarding
the potential anti-tumour effect of ZOL in combination with CT.
However, there are pre-clinical data from several different in vitro
and in vivo model systems of the beneficial anti-tumour effects of
combination therapy with anti-cancer agents and ZOL (Santini
et al, 2006). More specifically to breast cancer, beneficial effects of
the use of combination treatments including ZOL and cytotoxic
therapies have been shown in in vivo model systems of breast
cancer, most of which included a high degree of tumour-induced
bone disease. However, Ottewell et al (2008) recently reported that
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ssequential treatment with clinically relevant doses of doxorubicin,
followed 24h later by ZOL, inhibited subcutaneous breast tumour
growth in a mouse model of breast cancer soft tissue disease in the
absence of tumour bone disease. The two drugs alone or in the
reverse sequence had little or no effect on tumour growth.
Simultaneous administration of doxorubicin and ZOL also reduced
tumour growth somewhat, but only when the two drugs were given
in the sequence of doxorubicin followed by ZOL was complete and
durable inhibition of tumour growth achieved. The reduction in
subcutaneous tumour growth was accompanied by increased
tumour cell apoptosis, reduction in tumour cell proliferation and
tumour angiogenesis. The molecular mechanisms behind this
sequence-dependent synergy remain to be established, but giving
sequenced treatment elicited changes in the expression of a
number of genes and proteins associated with cell-cycle progres-
sion and apoptosis not occurring with single-agent doxorubicin or
ZOL (Ottewell et al, 2010). These data therefore suggest that low
serum concentrations of ZOL, in combination with cytotoxic
drugs, are sufficient to exert anti-tumour effects in peripheral
tissues and lead to the hypothesis that there may be beneficial anti-
tumour effects in patients with early breast cancer.
In summary, these are the first clinical data suggesting that the
addition of ZOL to neoadjuvant CT may improve pathological
response in breast cancer, and give further support to other
emerging data that ZOL may exhibit anti-tumour activity in
combination with anti-cancer therapies. Formal evaluation in
prospective neoadjuvant randomised trials incorporating detailed
assessment of biomarkers is recommended.
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